The Effect of Targeted Magnetic Nanopaticles on Hepatoma and the Expression of Bcl-2/bax Protein

Overview

Journal J Huazhong Univ Sci Technolog Med Sci

Specialty General Medicine

Date 2008 Aug 16

PMID 18704308

Citations 1

Authors

Jianming Wang

BaoLai Xiao

Jianwei Zheng

Shengquan Zou

Affiliations

Soon will be listed here.

Abstract

The effect of targeted magnetic nanoparticles on hepatoma and the underlying mechanism were examined. Nude mice transplanted with a human hepatoma cell line (HepG2 cells) were randomized into 5 groups, including: (1) group A, receiving normal saline, (2) group B, receiving 5-fluorouracil (5-Fu), (3) group C, receiving magnetic nanoparticles containing 5-Fu, (4) group D, consisting of treatment with magnetic nanoparticles containing 5-Fu and inside magnetic field and (5) group E, receiving pure magnetic nanoparticles and inside magnetic field. Morphological features of transplanted tumors in mice in each group were observed under transmission electron microscope (TEM). The expression of bcl-2/bax protein was immunohistochemically detected by SABC method. The results showed that a large number of apoptotic tumor cells were found in group B and group D under TEM. The expression of bcl-2 protein was significantly decreased and the expression of bax protein increased significantly in both group B and D as compared with those in group A, C and E (P<0.01 for all). The decrease in bcl-2 and the increase in bax were more in group D as compared with group B (P<0.01). It is concluded that the targeted magnetic nanoparticles containing 5-Fu can improve the chemotherapeutic effect of 5-Fu by decreasing bcl-2 expression, increasing bax expression and inducing apoptosis of the liver cancer cells.

Citing Articles

Effects of ursolic acid on the proliferation and apoptosis of human ovarian cancer cells.

Wang X, Li L, Wang B, Xiang J J Huazhong Univ Sci Technolog Med Sci. 2009; 29(6):761-4.

PMID: 20037823 DOI: 10.1007/s11596-009-0618-y.

References

Zhou X, Tang Z, Yu Y, Yang B, Lu J, Lin Z . Recurrence after resection of alpha-fetoprotein-positive hepatocellular carcinoma. J Cancer Res Clin Oncol. 1994; 120(6):369-73. DOI: 10.1007/BF01247463. View

Parkin D, Pisani P, Ferlay J . Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer. 1999; 80(6):827-41. DOI: 10.1002/(sici)1097-0215(19990315)80:6<827::aid-ijc6>3.0.co;2-p. View

Dizon D, Kemeny N . Intrahepatic arterial infusion of chemotherapy: clinical results. Semin Oncol. 2002; 29(2):126-35. DOI: 10.1053/sonc.2002.31680. View

Yan X, Fraser M, Qiu Q, Tsang B . Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner. Gynecol Oncol. 2006; 102(2):348-55. DOI: 10.1016/j.ygyno.2005.12.033. View

Yang E, Zha J, Jockel J, Boise L, Thompson C, Korsmeyer S . Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell. 1995; 80(2):285-91. DOI: 10.1016/0092-8674(95)90411-5. View

Blum H . Molecular targets for prevention of hepatocellular carcinoma. Dig Dis. 2002; 20(1):81-90. DOI: 10.1159/000063163. View

Tang Z, Sun F, Tian J, Ye S, Liu Y, Liu K . Metastatic human hepatocellular carcinoma models in nude mice and cell line with metastatic potential. World J Gastroenterol. 2002; 7(5):597-601. PMC: 4695559. DOI: 10.3748/wjg.v7.i5.597. View

Tanioka H, Tsuji A, Morita S, Horimi T, Takamatsu M, Shirasaka T . Combination chemotherapy with continuous 5-fluorouracil and low-dose cisplatin infusion for advanced hepatocellular carcinoma. Anticancer Res. 2003; 23(2C):1891-7. View

Keane M, Ettenberg S, Nau M, RUSSELL E, Lipkowitz S . Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res. 1999; 59(3):734-41. View

10.

Juin P, Hunt A, Littlewood T, Griffiths B, Swigart L, Korsmeyer S . c-Myc functionally cooperates with Bax to induce apoptosis. Mol Cell Biol. 2002; 22(17):6158-69. PMC: 133996. DOI: 10.1128/MCB.22.17.6158-6169.2002. View

11.

Murata K, Shiraki K, Kawakita T, Yamamoto N, Okano H, Nakamura M . Low-dose chemotherapy of cisplatin and 5-fluorouracil or doxorubicin via implanted fusion port for unresectable hepatocellular carcinoma. Anticancer Res. 2003; 23(2C):1719-22. View

12.

Grivicich I, Regner A, da Rocha A, Kayser G, Schunemann D, Grass L . The irinotecan/5-fluorouracil combination induces apoptosis and enhances manganese superoxide dismutase activity in HT-29 human colon carcinoma cells. Chemotherapy. 2005; 51(2-3):93-102. DOI: 10.1159/000085617. View

13.

Wang Z, Song W, Aboukameel A, Mohammad M, Wang G, Banerjee S . TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and invasion in pancreatic cancer. Int J Cancer. 2008; 123(4):958-66. PMC: 3766317. DOI: 10.1002/ijc.23610. View

14.

Shuto T, Kinoshita H, Hirohashi K, Kubo S, Tanaka H, Tsukamoto T . Indications for, and effectiveness of, a second hepatic resection for recurrent hepatocellular carcinoma. Hepatogastroenterology. 1996; 43(10):932-7. View

15.

KERR J, Winterford C, Harmon B . Apoptosis. Its significance in cancer and cancer therapy. Cancer. 1994; 73(8):2013-26. DOI: 10.1002/1097-0142(19940415)73:8<2013::aid-cncr2820730802>3.0.co;2-j. View

16.

Pohl J, Zuna I, Stremmel W, Rudi J . Systemic chemotherapy with epirubicin for treatment of advanced or multifocal hepatocellular carcinoma. Chemotherapy. 2001; 47(5):359-65. DOI: 10.1159/000048544. View

17.

Kogure T, Ueno Y, Iwasaki T, Shimosegawa T . The efficacy of the combination therapy of 5-fluorouracil, cisplatin and leucovorin for hepatocellular carcinoma and its predictable factors. Cancer Chemother Pharmacol. 2003; 53(4):296-304. DOI: 10.1007/s00280-003-0725-6. View

18.

Yao H, Li P, Venters B, Zheng S, Thompson P, Pugh B . Histone Arg modifications and p53 regulate the expression of OKL38, a mediator of apoptosis. J Biol Chem. 2008; 283(29):20060-8. PMC: 2459274. DOI: 10.1074/jbc.M802940200. View

19.

Duan X, Ou J, Li Y, Su J, Ou C, Yang C . Dynamic expression of apoptosis-related genes during development of laboratory hepatocellular carcinoma and its relation to apoptosis. World J Gastroenterol. 2005; 11(30):4740-4. PMC: 4615422. DOI: 10.3748/wjg.v11.i30.4740. View

20.

Clark J, GLICKSMAN A, Wanebo H . Systemic and adjuvant therapy for patients with pancreatic carcinoma. Cancer. 1996; 78(3 Suppl):688-93. DOI: 10.1002/(SICI)1097-0142(19960801)78:3<688::AID-CNCR50>3.0.CO;2-R. View